AI Science Tracker
EN

CEACAM6 as a machine learning derived immune biomarker for predicting neoadjuvant chemotherapy response in HR+/HER2- breast cancer.

Affiliation not stated in the reviewed material · 27 Aug 2025 · medicine

Discovery

CEACAM6 as a machine learning derived immune biomarker for predicting neoadjuvant chemotherapy response in HR+/HER2- breast cancer.

Source check: Source checked. Not independent scientific confirmation.

Finding / tested result: Methods 2.1: 956 HR+/HER2− GEO cases, five train/four test datasets; Results: 10-algorithm analysis, NeuralNet AUC .816; retrospective 106-patient cohort and paired IHC n=9. Biomarker association, no proven treatment benefit.

Technology: Machine-learning classifiers rank CEACAM6-related features and evaluate association with neoadjuvant chemotherapy response.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Machine-learning classifiers rank CEACAM6-related features and evaluate association with neoadjuvant chemotherapy response.
Limitation / still unknown
Results are limited to the reported models, cohorts, datasets or experiments; broader generalization and clinical or operational benefit were not established.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1662004/full

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.

Related catalog entries

Links use documented relationships where available, plus shared catalog context. A shared topic or model family does not establish a scientific dependency.